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The principal rationale for the use of anliarrhythmic drugs in 
patients with congestive heart failure is to prevent the 
occurrence of sudden death. Of the 2.066 deaths in natients 
with chronic heart failure reponed in long-ten burvival 
studies (I-15). 997 deaths (46%) were classified as sudden, 
although the incidence rate varied from 4 to 86% depending 
on the definition ofsudden death used. In our own series of 
Table 1. Relation 0fNe”roendocri”e Acdvadon and Sudden 
Death in 219 Patients with Con&w Heart Failure Followed Up 
for 14 2 17 Months 
219 patients (Rouleau J-L and Chattejee K. unpublished 
observations), sudden death was defined ar death occurring 
unextxctedlv within I h of onset of svm~lom~ in a oatienl 
whoappear~d clinically stable withoil a change in’symp- 
tams of heart failure durine the mecedine 24 h. Of the 99 
patients who died doting a m&o foll&up period of 34 
months, 35 (35%) died soddenly. 
Predictors of sodden death in chmnic heart failore. Al- 
though a number of hemodynamic and clinical variables 
have been identified that Presage the long-term outcome of 
patients with congestive heart failure. most of these factors 
appear to predict total mortality but not the ~~corrence of 
sudden death. For example, although left ventricular func- 
tion is a powerful prognostic indicator. patients dying of 
pmaressive heart failure and those dying suddenlv are -. T 
stmdar with respect lo the hemodynamic &erity of their 
disease 0. Similarly, althouzb the measurement of circulal- 
ing neurohormonesbrovide;imponant prognostic infomta- 
lion. patients with the most marked elevation of plasma 
catecholamines and plasma renin activity usually die of 
progressive Pomp dysfunction rather than soddenly (16). lo 
our long-term study of 219 patients with chronic heart 
failure. values for olasma renin aclivitv and olosma nored- 
nephrine were lo& in patients who died soddenly lhao’in 
tMients who died with twxressive symotoms (Table I). 
Mean values for plasma Ain activily~anh plasma norepi- 
nephrine ia patients in the sudden death group were similar 
to those in patients who were still alive at the time of their 
mos! recent f&ow-up visit. 
heart failure. but in contrast to many other variables. 
ventricular arrhythmias not only are independent predictors 
of total mortality but also presage the occurrence of sudden 
death (10.15,17,18). In a series of 43 patients studied by 
Holmes et al. (12). the mortality rate after I4 months was 
I I% in patients wilb simple ventricular arrhythmias but 59% 
in those with comolex ventricular eclopic rhythms: most of 
these deaths were-sudden. Similar obskrvatibns were made 
by Chakko and Gheorghiade (IO). who noted a strong 
association between the finding of nonsustained ventricular 
tachycardia on ambulatory electrocardiographic monitoring 
md the subsequent occurrence of sodden death. lo a study 
of 84 patients with hean failure. Dargie et al. (IS) found the 
fxquency of ventricular arrhythmias to be the most impor- 
tant iodependent predictor of total mortality sod sudden 
death. The I year mortality rote was approximately 50% in 
patients who had >720 ventricular extrasvst~les a day, but 
only about IO%in patients with fewereclopic beats. F&lly. 
veo~ricular tachycardia war the best predictor of sodden 
death in 300 patients with mild lo moderate heart failure 
followed up for 6 lo 24 months (18). Although some invesli- 
@ors (3.7) would disagree with these findings. it would 
seem reasonable loassess the risk of sudden death in chronic 
heart failure by assessing the frequency and complexity of 
asymptomatic ambulatory ventricular arrhythmias in these 
patients. 
Effect of hemndynamic interventions oo ventricular 
wrhylbmias. How should we manage these arrhythmias and 
reduce the risk of sudden death in congestive heart failure? 
Despite our hopes. pharmacologic interventions that im- 
prove the hemodynamic and clinical status of patients with 
ch,onic heart failure have not reduced the freooencv of 
ventricular arrhythmias or the incidence of sodden death. 
Although a combination of hvdmlazine and isonorbide dini- 
Wale c;n increase cardiac o;tpol, lower veolricolar filling 
pressures md reduce 1 ,!al mortality in these patients (19). 
there is no evidence that these agents ior any direct-acting 
vasodilator drug) can decrease the occurrence of unexpected 
anhythmic events. Similarly, although left ventticular per- 
formance may improve markedly after treatment with potent 
inotmpic agents such as the catecholtines and the phos- 
phodiestemse inhibitors. longterm treatment does not ie- 
duce the incidence of sudden death (20) and may increase 
(rather than decrease) the frequency o?serious arrhythmias. 
O/all therapeutic inrervcntions in the trearnwnl of heart 
faibrre. only the converdng-enzytw bhibimrs produce a 
significant decrease in the Jreqrrency and complexity of 
wmricrdar nrrhyrhmias in fbesepnrienf~ (2/,22J. The mech- 
anisms responsible for these beneficial etTecls of captopril 
and enalapril are not known. although some invesligalon 
have suggested that the reduction in plasmacalecholamioes 
or the repletion of total body potassium may play important 
contributory roles. Despite this apparent antianbylhmic 
r&on. however, converting enzyme inhibitors may not 
reduce the incidence of sodden death in chronic heart 
failure. In the CONSENSUS Study (14). enalaptil reduced 
the total mortality rate by 40% alter 6 months and by 31% 
after I? months of follow-up. but the incidence of sudden 
death was not altered by treatment. The reduction in total 
mortality in this study WOE attributed entirely lo a reduction 
in death from progressive congestive heart failure. 
These observations uggest hat therapy directed at ame- 
liorating the hemodynamic and neuroendocrine abnormali- 
ties of chronic heart failure does not favorably influence the 
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incidence of sudden death in this disorder. ConsequentlY, 
antiarrhythmic drugs need to he considered as a means of 
reducing the occurrence of lethal ventricular arrhythmias 
and improving the prognosis of these patients. 
Conventional ntiarrhythmic drug therapy in chronic heart 
failure. Most antiarrhythmic drugs are not an eEective ap- 
preach to the treatment of ventricular arrhythmias in pa- 
tients with congestive heart failure (23). In addition to their 
limited efficacy in patients with poor left ventricular func- 
tion. antiarrhvthmic agents can be proarrhvthmic, pwticu- 
lady in pat&s with h&t failure; thk result& exac&bation 
of arrhythmias may be sufficiently life threatening so as to 
neutralize any potential benefit of therapy in reducing 
arhythmic deaths. Moreover, virtually all antiarrhythmic 
drugs can cause worsening heart failure as a result of their 
cardiodemessant effects. If such ar. action increases the risk 
of death from progressive heart failure, no decrease in total 
mortality would he seen during long-term treatment with 
these drugs, even if lethal arrhythmic events were pre- 
vented. 
These elecrrophysiologic and hemodynamic limit&m 
may explain why conventional antiarrhylhmic drugs QWI~S 
have not been shown ‘o reduce the incidence of sudden 
dark in patients wkk chronic heart failure, whether these 
drugs have been administered empirically or whether treat- 
ment has been guided by the results of electmphysiologic 
stimulation. Chakko and Gheorghiade (IO) compared the 
long-term outcome of 23 patients with heart failure who 
received empiric therapy with quinidine and pmcainamide 
with that of a nonrandomized control group of 20 patients 
who did not receive antiarrhythmic drugs. The two groups 
ivere comparable in relation to age, severity and etnology of 
heartfailureattd the frequencyandcomplexity ofventricular 
arrhythmias detected during ambulatory electrocardio- 
graphy. Nevertheless, total mortality and the incidence of 
sudden death were similar in the two groups, suggesting a 
lack of benefit from antiarrhythmic therapy with these type 
IA drugs. Similar conclusions were drawn by Ludmer and 
Colucci (241, who observed little effect of treatment with 
quinidine and procainamide oit the incidence of sudden 
death in patients with chronic heart failure treated with 
milrinone. 
Unfortunately, in neither ofthese two studies (10,241 was 
the dose of quinidine and pro&amide titrated in an effort to 
suppress the occurrence of spontaneous or provoked 
arrhythmias. Most electrophysiologists now condemn such 
empiric use of antiarrhythmic drugs and favor an individu- 
alized approach based on the ability of drugs to halt the 
induction of sustained arrhythmias induced during electrical 
stimulation. It is not clear, however, that the disappointing 
thempa ic response to antiarrhythmic drugs in the two 
studies cited would have been more favorable if the use of 
these agents had been guided by the results of electmphy- 
siologic stimulation. The ability of electmphysiologic teSting 
to predict the owxrence of future atrhythmic events is 
limited in patients with asymptomatic arrhythmias. ape- 
cially in patients with an i “ypathic cardiomyopathy (25,26). 
This experience contrasts with the established utility of 
electrophysiologic testing in patients with symptomatic 
xrhvthmias. uarticularlv in the setline of ischemic heart 
dis&e (Z&zs’). 
All of these studier (1024-28) utilized pmcainamide and 
quinidint in an unsuccessful attempt o reduce the incidence 
of lethal arrhythmias. Unfortunately. such type IA agents 
may be of limited efficacy in patients with chronic heart 
failure. 
Antlarrhythmlr effects of amlodrmnc in ckmnic heart 
filure. In contrast to quinidine and procainamide, a recent 
double-blind, placebo-controlled, crossover study by Cle- 
land et al. (29) showed that amicdamne may substantially 
reduce the frequency and complexity of asymptomatic ven- 
tricular arrhythmias in patients with chronic heart failure. 
Treatment with amiodarone @ItI mglday) for 3 months was 
exceptionally effective in suppressing ambulatory arrhyth- 
mias and exerted no adverse effects on cardiac performance 
or exercise tolerance. Three patients died suddenly in this 
trial while receiving placebo,~whereas no patient died sud- 
denly during amiodarone therapy (although one patient 
experienced anonlethal prowrhythmic event). It is notewor- 
thy that few antiamhythmic agents have been shown to be 
effective in patients with chmnic heart failure when evalu- 
ated in double-blind, placebo-controlled trials. Conse- 
quently, the observations of Cleland et al. (29) suggest hat 
amiodarone may be supxior in eUIcacy to other antiarrhyth- 
mic drugs. Although this drug olten produces serious ad- 
verse effects when used in hi8h doses in patients with 
symptomatic arrhythmias, the low doses (ZCQ mglday) of 
amiodamne used by Cleland et al. to treat asymptomatic 
arrhythmias were both effective and well tolerated. 
reduce the incidence oj sudden deafi in patients I& 
chronic heart failure. Simonton et al. (20) found that anti- 
arrhythmic therapy decreased the frequknci of sudden death 
in 82 patients treated with phosphodiesterase inhibitors (Fig. 
I). In this study, sudden death occurred during the tirst 6 
months of follow-up in 29% of the 43 v&rats not treated 
with antiarrhythmicdrugs but in only lk of the 39 patients 
who received antiarrhythmic agents (which included amio- 
damn& Similar results were obtained by Neri et al. (301, 
who evaluated 65 patients with an idiopathic dilated car- 
diomyopathy. The 39 patients who had complex ventricular 
arrhythmias on ambulatory electrocardiographic monitoring 
were treated with amiodamne. whereas the 26 patients who 
did not have arrhythmias served as the control group. 
Amiodamne produced a substantial (64%) reduction in the 
frequency of ventricillm extmsystoles in 70 to 80% of 
patients during a follow-up period of 3 years. Despite a high 
Pfgm 1. Cumulative pmpwtion 0C patients with chronic hearc 
failure surviving without sudden death in relation to antiarrbythmic 
drug treatment. All 82 patients received long-term therapy with a 
phospMiestew inhibitor in addition to conventional treatment 
fw kart failure. Of the 82 patients enrolled in this study, 43 patients 
received w amiarrbylhmic drum Wed Nrl*i) and 26 of 39 
tMienls received type IA agent (quinidine 01 pmcainamide) and I3 
reeeiv&.mi&mne(drrW. ‘knumbecofpatientravailable 
for lnltowup at each time interrat are shown. itepwduced with 
ALAR flum fief. 20. 
incidettce of venIrictdar tachyctiia during the baseline 
period, no palient treated with amiwkuone died suddenly, 
allhough many patients died of progressive heart failure. 
Minor side effects attributed to amiodarone were cmtxn~n. 
but only four patients had to discontinue therapy because of 
a major adverse reaction. 
Finafly, in B prospeclive study ofpatients with moderate 
to severe heart faiturp, Dar& et al. (1St suggested that 
raG&ame can reduce &~a~ mortality in this diier. Of 
the t34 patients enrolled in this t&d, 29 patients were treated 
with and&mm Matt dose, 16.3 mgIdayt. whereas the 
remaining 55 patients received no antiaxrhythmic drugs. 
Although patients were not randomly assigned to their 
treatment groups, the two groups were similar with respect 
to all pretreatment prognostic variables (e.g.. cawe of heart 
failure. severity of ventricular dysfunction and exercise 
intolerance, the level of circulating neumhormones and the 
Ftiuen$y of arrhythmias). Nevertheless, patients treated 
anuodarone hada I yewzwatity ~~~~IYa~ut IQ% 
compared with a nearly 4S% atonality rate in patients who 
were n&treated with thedtug (Fib& 2). ~spitethe~e~ts of 
amiodamtw therapy, mwt patients still died suddenly in this 
study. Although a selection bii cannot be ruled out in this 
nonrandomized t&4, these observations trongly suggest hat 
antiarrhythmic therapy with amiodamne can decrew the 
incidence of sudden death and improve the overall prognosis 
ofpatients with severe chronic hart failure. 
Caeksior. Latge scale, randomized controlled clinical 
trials are clearly needed to establish me ability of anti- 
~y~mie drugs to decrease total mortality and sudden 
death in patients with chmnic heart failure who have asymp- 
torn& arrhythmias. Until the results of such studks are 
available, however, antiarrhythmic agents @articularly amiw 
damnekalon~ with aatesrive treatment of the symr~toms of
heart failu&shwld-k given wious conside&& in the 
overallman~eementofthe~~atientwithchronicheartfailunin 
whom malig&tI vetmictd& arrhythmias are detected. 
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Despite the presence of frequent and complex ventricular 
arrhythmias, must patients with chmnic congestive heart 
failure probably should not be given antiarrhylhmic agents 
for the treatment of asymptomatic ventricular rhythm dis 
turbances. In patients who have symptomatic ventricular 
arrhythmias, the goals of antiarrhythmic therapy are the 
supressian of symptoms and the prevention of sudden car- 
diac death. In patients with asymptomatic ventricular 
arrhythmias, however, treatment can onlv be directed at 
preknting lethal arrhythmic events. U&rtunately, it is 
difficull to establish a loeical rationale for treathw the 
asymptomatic patient be&e it is not known whether the 
suppression of asymptomatic ventricular arrhythmias will 
prevent sudden death. This uncertainty must be weighed 
winst the knowled!ae that all antiarrhythmic drues nroduce 
s;bstantial side e&s (including the r&k ofena&b&ng the 
arrhythmia) that can be lethal. Thus. althoueh some uatients _ . 
witd chronic heart failure are likely to benefit from anti- 
arrhythmic theraw. it is imuortanl to analwe the risk/benefit 
ratid associated &h ihe &tment of these patients. 
Risk of asymptomatic arrhythmias in cbronlc heari fedture. 
The frequency and complexity of ventricular arrhythmias 
@.rticularly nonsustained ventricular tachycardia) are major 
risk factors for sudden cardiac death (l-14). although the 
precise nature of the relation between nonsustained ventricu- 
lar tachycardia nd sudden cardiac death remains unclear. It 
is possible that nonsustained ventricular tachycardia may 
actually trigger the nnset of sustained ventricular tachycardia 
or fibrillalion; it may itself become sustained at a given point 
in time (although such a transformation is uncanmun in my 
experience) or it may merely w-a as a marker of a ventricle 
that is capable of supporting more serious arrhythmias. 
